BioXcel Therapeutics Inc. (BTAI)
$1.20
$0.01
(0.84%)
As on 18-Jun-2026 16:36EDT
Market cap
$35 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
27.5
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-17.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.8
-
Debt to Equity
-0.7
-
Book Value
$--
-
EPS
$-6.2
-
Face value
--
-
Shares outstanding
30,877,605
9 Years Aggregate
CFO
$-483.41 Mln
EBITDA
$-573.68 Mln
Net Profit
$-598.44 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
BioXcel Therapeutics (BTAI)
| -25.0 | 5.3 | -30.6 | -26.8 | -84.5 | -71.1 | -- |
|
BSE Sensex*
| -9.3 | 2.0 | 0.1 | -5.7 | 6.6 | 8.0 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
BioXcel Therapeutics (BTAI)
| -73.3 | -87.1 | -86.3 | 5.7 | -56.0 | 216.2 | 278.5 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
BioXcel Therapeutics (BTAI)
|
1.2 | 35.2 | 0.7 | -75.3 | -8,550.7 | -- | -- | 27.5 |
| 278.1 | 37,764.0 | 4,286.9 | 577.2 | 20.3 | 88.2 | 70.9 | 35.1 | |
| 230.8 | 14,299.5 | 867.5 | 506.6 | -0.6 | -- | 25 | 25.4 | |
| 51.9 | 13,354.5 | 2,375.5 | 833.4 | 41.5 | 40.7 | 17.6 | 6.9 | |
| 167.8 | 29,936.9 | 16,632.0 | 1,385.0 | 14.1 | 22.3 | 22.3 | 4.9 | |
| 505.8 | 11,084.5 | 1,132.5 | -309.4 | -25.0 | -52.9 | -- | 20.4 | |
| 460.2 | 13,347.1 | 2,678.3 | 460.4 | 21.3 | 103.2 | 29.4 | 22.3 | |
| 609.9 | 64,176.2 | 14,919.6 | 4,423.4 | 34.9 | 14.2 | 14.9 | 2.0 | |
| 536.6 | 23,174.2 | 3,169.8 | 1,287.4 | 51.3 | 20.6 | 20.2 | 3.9 | |
| 451.6 | 112,924.4 | 12,255.1 | 4,338.3 | 32.0 | 23.7 | 26.4 | 5.8 |
Shareholding Pattern
View DetailsAbout BioXcel Therapeutics (BTAI)
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United... States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. Read more
-
Founder, CEO, President, & Director
Dr. Vimal D. Mehta Ph.D.
-
Founder, CEO, President, & Director
Dr. Vimal D. Mehta Ph.D.
-
Headquarters
New Haven, CT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for BioXcel Therapeutics (BTAI)
What is the current share price of BioXcel Therapeutics Inc (BTAI) Today?
The share price of BioXcel Therapeutics Inc (BTAI) is $1.20 (NASDAQ) as of 18-Jun-2026 16:36 EDT. BioXcel Therapeutics Inc (BTAI) has given a return of -84.49% in the last 3 years.
What is the current PB & PE ratio of BioXcel Therapeutics Inc (BTAI)?
Since, TTM earnings of BioXcel Therapeutics Inc (BTAI) is negative, P/E ratio is not available.
The P/B ratio of BioXcel Therapeutics Inc (BTAI) is 27.50 times as on 12-Jun-2026, a 564 premium to its peers’ median range of 4.14 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.27
|
-0.20
|
|
2024
|
-0.02
|
-0.01
|
|
2023
|
-0.03
|
-0.10
|
|
2022
|
-0.26
|
0.56
|
|
2021
|
-0.38
|
0.18
|
What is the 52 Week High and Low of BioXcel Therapeutics Inc (BTAI)?
The 52-week high and low of BioXcel Therapeutics Inc (BTAI) are Rs 8.08 and Rs 1.01 as of 20-Jun-2026.
What is the market cap of BioXcel Therapeutics Inc (BTAI)?
BioXcel Therapeutics Inc (BTAI) has a market capitalisation of $ 35 Mln as on 12-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in BioXcel Therapeutics Inc (BTAI)?
Before investing in BioXcel Therapeutics Inc (BTAI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.